MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
FULC - Fulcrum Therapeutics Inc
$12.77
-1.26(-9.02%)8:56:32 PM 2/25/2021
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
Stock Statistics
MarketCap458M
PE Ratio
PEG Ratio-0.8
P/B2.5
P/S (ttm)79.4
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %5%
Held by Institutions %76%
1 Day Vol Adjusted Return-1.7
1 Month Vol Adjusted Return1.1
3 Month Vol Adjusted Return4.2
6 Month Vol Adjusted Return13.6
20 Days SMA Price ZScore-0.1
50 Days SMA Price ZScore0.2
12 -26 Days PPO3.6
1 Month Average Short Volume Ratio38.2
1 Day Volume Change ZScore-0.7
1 Month Daily Vol5.3
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/19/2021FULC
    Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: Virtual SVB Leerink 10th Annual Global Healthcare ConferencePresentation on Thursday, February 25, 2021 at 10:40 a.m. ET. Virtual H.C. Wainwright Global Life Sciences ConferencePrerec...

    02/17/2021FULC
    What Type Of Shareholders Own The Most Number of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares?

    The big shareholder groups in Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) have power over the company. Generally...

    01/22/2021FULC
    Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

    CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $11.00 per share, which includes 600,000 shares issued upon the exercise in full by the underwriters of their option to purchase...

    01/20/2021FULC
    Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share, for total gross proceeds of $44.0 million, before deducting underwriting discounts and commissions and offering expenses pay...

    01/19/2021FULC
    Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Fulcrum. In addition, Fulcrum expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its co...

    01/19/2021FULC
    Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer

    Owen Wallace to Transition to Scientific Advisory BoardCAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Christopher Moxham, Ph.D., has been promoted to the role of chief scientific officer. In this role, Dr. Moxham will oversee the organization’s full range of drug discovery and translational science resea...

    01/6/2021FULC
    Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference

    CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference. A webcast will be available on-demand on Monday, January 11, 2021 at 6:00 a.m. ET through the H.C. Wainwright conference portal and on the Investor Relation...

    12/10/2020FULC
    Is FULC A Good Stock To Buy Now?

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]